Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDillistone Regulatory News (DSG)

Share Price Information for Dillistone (DSG)

Share Price is delayed by 15 minutes
Get Live Data
11.50    -0.20 (-1.74%)
Bid:
11.00
Ask:
12.00
Spread: 1.00 (9.091%)
Market Cap: £4.00m
DSG Live PriceLast checked at - London Stock Exchange

Intraday Dillistone Share Chart

Directorate Change

12 Apr 2010 09:30

RNS Number : 0209K
Dillistone Group PLC
12 April 2010
 



12 April 2010

 

 

DILLISTONE GROUP PLC

 

BOARD APPOINTMENT

 

Dillistone Group Plc ("Dillistone" or the "Company"), the AIM quoted supplier of recruitment software, is pleased to announce that Julie Patricia Pomeroy will join the board of Dillistone ("Board") as Finance Director with effect from 19 April 2010.

 

Julie, 54, is an experienced finance director of quoted and private companies and the Board is confident that she will be an asset to the Company. Julie graduated with an honours degree in physics from Birmingham University. She is a Chartered Accountant and Chartered Director as well as holding tax and treasury qualifications. Julie was group finance director of Carter & Carter Group plc until October 2005 having joined in 2002 to help grow and float the business. She had previously been chief financial officer of Weston Medical Group plc and prior to this, Julie worked at East Midlands Electricity plc as director of corporate finance. In August 2006 Julie was appointed to the role of finance director of AIM quoted Biofutures International plc and will continue in this role. Julie is also a non-executive director of Nottinghamshire Healthcare NHS Trust.

 

Mike Love, Chairman of Dillistone, commented:

"We are delighted to welcome Julie to the Board. We believe that Julie's experience as a director of both private and public companies will be an invaluable asset to the Company in her role as Finance Director. We look forward to Julie making a significant contribution to the continued development of Dillistone."

 

Julie is currently a director of Biofutures International Plc.

 

In the past 5 years Julie has been a director of the following companies:

 

Carter and Carter Group plc

Carter and Carter Limited

Carter and Carter Apprentice Learning Limited (previously EMTEC Holdings Limited)

EMTEC Colleges Limited

EMTEC (Specialised Services) Limited

EMTEC (Leicestershire) Limited

EMTEC (Derbyshire) Limited

Motor Systems Limited

 

Julie Pomeroy resigned as a director of WGP 1 Limited (formerly known as Weston Medical Group plc), WGP 100 Limited (formerly known as Weston Medical Limited) and WMG (1) Limited (formerly known as Intraject Limited) on 30 November 2002. These companies went into members voluntary liquidation on 28 February 2003 which has now been completed with a small return to shareholders.

 

 

Julie does not hold any shares in Dillistone.

 

In accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies, the Company confirms that there are no further matters to be disclosed in respect of Julie Pomeroy's appointment.

 

Contacts:

 

Mike Love Dillistone Group Plc 0207 749 6100

Chairman

 

Jason Starr Dillistone Group Plc 0207 749 6100

Managing Director

 

Emily Staples (Nomad) Religare Capital Markets 0207 444 0800

 

Daniel Briggs (Broker) Religare Capital Markets 0207 444 0500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGUQPCUPUUMP
Date   Source Headline
7th May 20267:00 amRNSFinal Results & Investor Presentation
24th Apr 20267:00 amRNSNotice of Final Results & Investor Presentation
9th Mar 20262:44 pmRNSHolding(s) in Company
9th Mar 20262:44 pmRNSHolding(s) in Company
9th Mar 20262:23 pmRNSHolding(s) in Company
9th Mar 20262:23 pmRNSHolding(s) in Company
2nd Mar 20263:08 pmRNSHolding(s) in Company
25th Feb 202611:40 amRNSHolding(s) in Company
25th Feb 202610:09 amRNSHolding(s) in Company
23rd Feb 20262:28 pmRNSResult of GM & Directorate Change
11th Feb 202612:59 pmRNSHolding(s) in Company
5th Feb 202611:28 amRNSResult of Placing and Subscription
4th Feb 20264:47 pmRNSProposed Placing and Subscription
30th Sep 20257:00 amRNSInterim Results & Investor Presentation
11th Sep 20257:00 amRNSNotice of Interim Results & Investor Presentation
4th Jun 202511:50 amRNSResult of AGM
4th Jun 20257:01 amRNSAGM Statement
4th Jun 20257:00 amRNSRelated party loan
9th May 202511:32 amRNSDirectorate Declaration
8th Apr 20257:00 amRNSFinal Results & Investor Presentation
3rd Apr 20257:00 amRNSNotice of Results & Investor Presentation
5th Feb 20257:00 amRNSTrading Update & Notice of Results
4th Dec 20247:00 amRNS-ROpenAI powered Interview Simulation Platform
17th Sep 20247:00 amRNSInterim Results & Investor Presentation
11th Sep 20247:00 amRNSNotice of Results & Investor Presentation
2nd Sep 20249:45 amRNSHolding(s) in Company
29th Aug 20248:30 amRNSHolding(s) in Company
23rd Aug 20247:00 amRNSTrading update and Fund Raising
15th Jul 20247:00 amRNSChange of Adviser
12th Jun 20241:40 pmRNSResult of AGM
12th Jun 20247:00 amRNSAGM Statement
25th Apr 20247:00 amRNSFinal Results & Investor Presentation
22nd Apr 20247:00 amRNSNotice of Results & Investor Presentation
9th Apr 20247:00 amRNSBlock listing Interim Review
30th Jan 20247:00 amRNSTrading Update & Notice of Results
9th Oct 20237:00 amRNSBlock listing Interim Review
26th Sep 20237:00 amRNSInterim Results & Investor Presentations
18th Sep 20237:00 amRNSNotice of Results & Investor Presentations
13th Jun 20231:18 pmRNSResult of AGM
13th Jun 20237:00 amRNSAGM Statement
25th Apr 20237:00 amRNSFinal Results & Investor Presentation
11th Apr 20237:00 amRNSBlock listing Interim Review
30th Mar 20237:00 amRNSContract & Notice of Results
2nd Feb 20237:00 amRNSTrading Update & Notice of Results
7th Nov 20227:00 amRNSDirector Dealings
10th Oct 20227:00 amRNSBlock listing Interim Review
26th Sep 20227:01 amRNSDirectorate Changes
26th Sep 20227:00 amRNSInterim Results & Investor Presentation
20th Sep 20227:00 amRNSNotice of Results & Investor Presentation
16th Jun 20228:00 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.